DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported that preliminary sales results were much stronger in the fourth quarter (ended June 30, 2011) than the initial three fiscal quarters, coming in at approximately $2,348,000. However, sales were not at the record levels originally expected. This was largely due to the fact that contract manufacturing revenues, originally forecast to be approximately $350,000 for the quarter, were not realized due to a key raw materials failure not under the control of the company. Given the preliminary fourth quarter sales noted above, the company’s preliminary sales results for the fiscal year ended June 30, 2011, will be approximately $7,942,000, or 3.8% below sales reported in the prior fiscal year.
